Category Archives: Regenerative Medicine

by admin on March 23, 2018 No comments

By: Matthew Fischer

The regenerative medicine arena consists of a wide range of innovative products. Congress, acknowledging the importance of this field, has established a new program via the 21st Century Cures Act to help spur development and provide for accelerated approval for regenerative medicine products similar to the FDAs fast track and breakthrough therapy designations. This new approval is the Regenerative Medicine Advanced Therapy (RMAT) Designation.

The RMAT Designation includes all the benefits of the FDAs other accelerated designations including early agency engagement and priority review; however, unlike the other designations, the RMAT Designation does not require evidence that the product offers substantial improvement over other therapies. For a drug to be eligible for the RMAT Designation, it must meet the following:

The Code of Federal Regulations sets forth specific guidelines for the designation request process. The office within the FDA tasked with reviewing these requests is the Office of Tissues and Advanced Therapies (OTAT).

In November 2017, the FDA issued draft guidance regarding this expedited program requesting comment from the industry. At the time, the FDA indicated that the agency had received 34 designation requests and acted on 31 of the requests. With this new regulatory framework and specific pathway, the FDA seeks to set the stage for the future with the goal of addressing unmet medical needs with reduced product development time.

Related

See the original post here:
The Regenerative Medicine Fast Track: What is the RMAT ...

Non-Operative Solutions for Orthopaedic Pain

Regenerative Medicine refers to the processes by which specialized technology is used to create living, functional tissues to replace or repair tissue that has been lost due to damage, disease, or hereditary defects. For those struggling with limited mobility due to arthritis, injury, tendinopathy (disease of the tendons), or other forms of musculoskeletal inflammation, patients may be able to experience relief and avoid surgery by harnessing the healing potential of their own cells.

Adipose-Derived Cell TherapiesThis method utilizes fat cells, which have high concentrations of stem cells and other growth factors within them, to decrease inflammation and aid in healing. In a minimally invasive procedure, a doctor will retrieve a patients own fat cells and deposit them into a device that uses a saline agent to rid the cells of blood and oil. At that point, the fat tissue has been resized and holds the ideal material and performance properties to stimulate healing. The doctor will then inject the fat graft into the joint experiencing the arthritic pain to decrease inflammation and encourage healing.

Platelet Rich PlasmaCommonly referred to as PRP, platelet rich plasma utilizes a patients own blood to produce growth factors. Growth factors are naturally occurring proteins that bind to the cells in your body and stimulate growth, healing, and repopulation. With this minimally invasive procedure, a doctor will draw the patients blood and spin it in a centrifuge to separate the blood into layers. The layer, which is rich with growth factors and platelets, is extracted and reintroduced into the damaged joint to encourage healing and reduce inflammation.

Bone Marrow AspirateBone marrow the soft, spongy tissue found in the center of large bones is composed of both fluid and solid matter. It is rich in growth factors and regenerative stem cells. Unlike other cells in the body, these cells are able to replicate themselves into various types of tissue for healing. To utilize bone marrow to stimulate healing and regrowth in an arthritic joint, a doctor will extract bone marrow fluid (called aspirate) from a healthy bone in the body, generally the pelvis, and place it in a centrifuge to generate a concentration of powerful cells. These cells are then reintroduced into the arthritic joint to repair damaged tissue and decrease inflammation.

These procedures are some of the newest treatments available today. They offer patients a minimally invasive option to help relieve the pain of arthritis or injury and improve function. Our highly skilled medical doctors use state-of-the-art diagnostic tools, including musculoskeletal untrasound, high-definition on-site MRI, and X-ray, to obtain pinpoint accuracy during the procedures.

Make an appointment with one of our industry-leading physicians today to see if Regenerative Medicine is an option for you by calling (423) 697-8780.

The physicians at Center for Sports Medicine and Orthopaedics are highly regarded as leaders in their profession, not only in Chattanooga, but in the Southeast region. They continue to be at the forefront of offering patients the latest medical procedures and treatments toward ensuring the best possible outcomes. We are excited to offer our patients an innovative approach to treating pain and healing.

At Center for Sports Medicine & Orthopaedics, our highly trained and compassionate staff takes pride in providing personalized care to all of our patients. That starts with a full orthopaedic evaluation with one of our doctors to assess your needs and evaluate your treatment options. We have specialists who focus on specific areas of the body including the spine, shoulder, hand, elbow, hip, knee, foot and ankle.

Make an appointment with one of our industry-leading physicians today to see if Regenerative Medicine is an option for you by calling (423) 697-8780.

regenerativemed@sportmed.com2415 McCallie AvenueChattanooga, Tennessee 37404

Read more from the original source:
Regenerative Medicine - sportmed.com

Regenerative Medicine

Regenerative medicine, where the body regenerates or rebuilds itself, is a relatively new and rapidly evolving front in the field of interventional pain management. Although stem cell therapy has garnered much of the attention over the past several decades, multiple other regenerative medicine modalities also have caught the publics attention. Our parent company Biotech Products Services & Research (BPSR) is a leader in developing new regenerative products and protocols.

Organicell provides the GOLD STANDARD of regenerative products for your medical practice. Our high quality, next generation, placental derived products may give a longer lasting and more profound improve quality of life for those suffering from diseases and disorders that involve pain and inflammation.

Organicell Flow is safe and easy to use. All products are tested using the highest standards for various pathogens. Organicell Flow has been independently tested to demonstrate viability. Our product contains: Pluripotent MSC, Growth Factors, Cytokines, Collagen, Hyaluronic Acid, and more.

ORGANICELL

Cells Helping Cells Makes Cellular Sense

The Human Body in Numbers

Continue reading here:
OrganiCell Regenerative Medicine Management

Though great progress has been made in medicine, current evidence-based and palliative treatments are increasingly unable to keep pace with patients' needs, especially given our aging population. There are few effective ways to treat the root causes of many diseases, injuries and congenital conditions. In many cases, clinicians can only manage patients' symptoms using medications or devices.

Regenerative medicine is a game-changing area of medicine with the potential to fully heal damaged tissues and organs, offering solutions and hope for people who have conditions that today are beyond repair.

Regenerative medicine itself isn't new the first bone marrow and solid-organ transplants were done decades ago. But advances in developmental and cell biology, immunology, and other fields have unlocked new opportunities to refine existing regenerative therapies and develop novel ones.

The Center for Regenerative Medicine takes three interrelated approaches:

Rejuvenation. Rejuvenation means boosting the body's natural ability to heal itself. Though after a cut your skin heals within a few days, other organs don't repair themselves as readily.

But cells in the body once thought to be no longer able to divide (terminally differentiated) including the highly specialized cells constituting the heart, lungs and nerves have been shown to be able to remodel and possess some ability to self-heal. Teams within the center are studying how to enhance self-healing processes.

Replacement. Replacement involves using healthy cells, tissues or organs from a living or deceased donor to replace damaged ones. Organ transplants, such as heart and liver transplants, are good examples.

The center aims to expand opportunities for transplants by finding ways to overcome the ongoing donor shortage, the need for immunosuppression and challenges with organ rejection.

Regenerative medicine holds the promise of definitive, affordable health care solutions that heal the body from within.

Stem cells have the ability to develop through a process called differentiation into many different types of cells, such as skin cells, brain cells, lung cells and so on. Stem cells are a key component of regenerative medicine, as they open the door to new clinical applications.

Regenerative medicine teams are studying a variety of stem cells, including adult and embryonic stem cells. Also being studied are various types of progenitor cells, such as those found in umbilical cord blood, and bioengineered cells called induced pluripotent stem cells. Each type has unique qualities, with some being more versatile than others.

Many of the regenerative therapies under development in the Center for Regenerative Medicine begin with the particular patient's own cells. For example, a patient's own skin cells may be collected, reprogrammed in a laboratory to give them certain characteristics, and delivered back to the patient to treat his or her disease.

Stem cells and their use in regenerative medicine have been in the media a lot lately. But what exactly does it mean? Physicians and researchers in the Center for Regenerative Medicine say it has to do with developing completely new ways to treat and manage chronic diseases such as diabetes, heart failure, and degenerative nerve, bone and joint conditions.

.

See the article here:
About Regenerative Medicine - Center for Regenerative ...

Regenerative medicine seeks to replace tissue or organs that have been damaged by disease, trauma, or congenital issues, vs. the current clinical strategy that focuses primarily on treating the symptoms. The tools used to realize these outcomes are tissue engineering, cellular therapies, and medical devices and artificial organs.

Combinations of these approaches can amplify our natural healing process in the places it is needed most, or take over the function of a permanently damaged organ. Regenerative medicine is a relatively new field that brings together experts in biology, chemistry, computer science, engineering, genetics, medicine, robotics, and other fields to find solutions to some of the most challenging medical problems faced by humankind.

When injured or invaded by disease, our bodies have the innate response to heal and defend. What if it was possible to harness the power of the body to heal and then accelerate it in a clinically relevant way? What if we could help the body heal better?

The promising field of Regenerative Medicine is working to restore structure and function of damaged tissues and organs. It is also working to create solutions for organs that become permanently damaged. The goal of this approach is to find a way to cure previously untreatable injuries and diseases.

1. Tissue Engineering and BiomaterialsTissue engineering is a strategy where biologically compatible scaffolds are implanted in the body at the site where new tissue is to be formed. If the scaffold is in the geometric shape of the tissue that needs to be generated, and the scaffold attracts cells the outcome is new tissue in the shape desired. If the newly forming tissue is subjected to exercise as it forms, the outcome can be new functional engineered issue.

Millions of patients have been treated with some form of tissue engineered devices, yet the field is in its infancy. The primary success stories have been with soft tissue regeneration. To learn more about some of the promising studies and clinical trials involving tissue engineering,click here.

2. Cellular TherapiesMany millions of adult stem cells are found in every human. Our body uses stem cells as one way of repairing itself. Studies have illustrated that if adult stem cells are harvested and then injected at the site of diseased or damaged tissue, reconstruction of the tissue is feasible under the right circumstances. These cells can be collected from blood, fat, bone marrow, dental pulp, skeletal muscle and other sources. Cord blood provides yet another source of adult stem cells. Scientists and clinicians are developing and refining their ability to prepare harvested stem cells to be injected into patients to repair diseased or damaged tissue.

To learn more about some of the promising studies and clinical trials involving cellular therapies,click here.

3. Medical Devices and Artificial OrgansIn cases where an organ fails, the predominant clinical strategy is to transplant a replacement organ from a donor. The principal challenges are the availability of donor organs, and the requirement that the donor take immunosuppression drugswhich have side effects. Further, there are many instances where the time to find a suitable donor organ requires an interim strategy to support or supplement the function of the failing organ until a transplantable organ is found. Using circulatory support as an example, there are technologies in various stages of maturity, initially using ventricular assist devices (VADs) as a bridge to a heart transplant, and now there are VADs that are used for long-term circulatory support (destination therapy).

Scientists and clinicians around the world are developing and evaluation devices to supplement or to replace the function of many organ systems including the heart, lung, liver and kidney.

To learn more about some of the promising studies and clinical trials involving medical devices and artificial organs, click here.

Here is the original post:
What Is Regenerative Medicine? | Regenerative Medicine at ...

Regenerative medicine may be defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function. This field holds the promise of regenerating damaged tissues and organs in the body by replacing damaged tissue or by stimulating the body's own repair mechanisms to heal tissues or organs. Regenerative medicine also may enable scientists to grow tissues and organs in the laboratory and safely implant them when the body is unable to heal itself. Current estimates indicate that approximately one in three Americans could potentially benefit from regenerative medicine.

Regenerative Medicine refers to a group of biomedical approaches to clinical therapies that may involve the use of stem cells. Examples include cell therapies (the injection of stem cells or progenitor cells); immunomodulation therapy (regeneration by biologically active molecules administered alone or as secretions by infused cells); and tissue engineering (transplantation of laboratory grown organs and tissues). While covering a broad range of applications, in practice the latter term is closely associated with applications that repair or replace portions of or whole tissues (i.e., bone, cartilage, blood vessels, bladder, skin). Often, the tissues involved require certain mechanical and structural properties for proper functioning. The term has also been applied to efforts to perform specific biochemical functions using cells within an artificially-created support system (e.g., artificial pancreas or liver).

Cord blood stem cells are being explored in several applications including Type 1 diabetes to determine if the cells can slow the loss of insulin production in children; cardiovascular repair to observe whether cells selectively migrate to injured cardiac tissue, improve function and blood flow at the site of injury and improve overall heart function; and central nervous system applications to assess whether cells migrate to the area of brain injury alleviating mobility related symptoms, and repair damaged brain tissue (such as that experienced with cerebral palsy). Cord blood stem cells likely will be an important resource as medicine advances toward harnessing the body's own cells for treatment. Because a person's own (autologous) stem cells can be infused back into that individual without being rejected by the body's immune system, autologous cord blood stem cells have become an increasingly important focus of regenerative medicine research.

Regenerative medicine has made its way into clinical practice with the use of materials that are able to assist in the healing process by releasing growth factors and cytokines back into the damaged tissue (e.g., (chronic) wound healing). As additional applications are researched, the fields of regenerative medicine and cellular therapies will continue to merge and expand, potentially treating many disease conditions and improving health for a variety of diseases and health conditions.

Follow this link:
Regenerative Medicine - AABB

Resource page

For the purposes of the information provided on this page we have adopted the definition of the term regenerative medicine that was used in the House of Lords Regenerative Medicine Report (see below). This was:

regenerative medicine is used to refer to methods to replace or regenerate human cells, tissues or organs in order to restore or establish normal function. This includes cell therapies, tissue engineering, gene therapy and biomedical engineering techniques, as well as more traditional treatments involving pharmaceuticals, biologics and devices.

Each regulator has a clear remit and regulates distinct areas of the regenerative medicine process. However, we work closely together to provide effective advice and guidance to support establishments through the regulatory requirements. Each regulator has a core set of standards that apply depending on where you are in the process, from cell derivation to treatment. We are all focused on ensuring that the standards that are applied at one stage of the process do not act as a barrier at another.

The role of each of the regulators in regenerative medicine is set out below:

Health Research Authority (HRA) has a remit to provide an ethics opinion on clinical trials. Those involving gene therapy regenerative medicines are reviewed through the Gene Therapy Advisory Committee (GTAC). Other regenerative medicine studies may be reviewed by other appropriately flagged RECs. It also provides the Integrated Research Application System (IRAS) through which applications and approvals from GTAC/RECs and MHRA for clinical trials involving regenerative medicines can be made.

Human Fertilisation and Embryology Authority (HFEA)[external link] regulates the use of human embryos or human admixed (human-animal) embryos to derive stem cells for use in the treatment of patients.

Human Tissue Authority (HTA) [external link] remit includes regulation of organisations that remove, store and use of human tissue or cells; this includes where they are used as starting materials for Advanced Therapy Medicinal Products (ATMPs). Under the European Union Tissues and Cells Directives (EUTCD), it licenses establishments that remove, test, process, store, and distribute tissues or cells that will (or may) be used to treat patients.

Medicines and Healthcare products Regulatory Agency (MHRA)[external link] remit includes responsibility for granting the appropriate authorisation for the manufacturing site of ATMPs, which are prepared and used under the hospital exemption, and for ATMPs made and supplied under the specials scheme under the relevant provisions in medicines legislation. In the area of clinical trials, the MHRAs remit includes assessment of applications for clinical trial authorisation and the associated manufacturers licence for investigational ATMPs. The National Institute for Biological Standards and Control (NIBSC) [external link], which houses the UK National Stem Cell bank, is part of the MHRA.

Please refer to the Research Community area of the website for information about the approvals for research studies and how to apply to individual review bodies. Further information about GTAC is also provided on this site. Additionally the Stem Cell Toolkit [external link] provides regulatory routemaps that are specific to individual stem cell projects.

Department for the Environment Food and Rural Affairs (DEFRA) [external link] has an Advisory Committee on Releases to the Environment (ACRE) [external link], which advises government on requests for permission to release genetically modified organisms (GMO) into the environment. In 2013, this committee published advice on gene therapy clinical trial for heart disease.

Health and Safety Executive (HSE) [external link] has the Scientific Advisory Committee on Genetically Modified Organisms (Contained Use) SACGM (CU) [external link]. This committee provides technical and scientific advice to the UK Competent Authorities on all aspects of the human and environmental risks, and is responsible for maintaining guidance on the contained use of GMOs.

From 13 October 2014, the MHRAs Innovation Office is the portal for all regulatory queries concerning regenerative medicines. A one stop shop service provides a single point of access from the four regulators in the field, the Human Tissue Authority (HTA), the Human Fertilisation and Embryology Authority (HFEA), Health Research Authority (HRA) and the Medicines and Healthcare products Regulatory Agency (MHRA), who will provide a co-ordinated single response service for free regulatory advice.

Any query relating to the regulation of regenerative medicines, including Advanced Therapeutic Medicinal Products (ATMPs) can be submitted to the MHRAs Innovation Office and will be answered by the relevant experts from the four regulatory bodies.

Individuals or companies who have regulatory questions concerning regenerative medicines and who are unsure which agency to direct their inquiry to, or have a query that impacts several regulators, should use the Innovation Office advice form.

The HRA and others work closely together and will continue to engage with those involved in regenerative medicine, including researchers, the British Society for Gene and Stem Cell Therapy [external link], and the Cell Therapy Catapult [external link] to help clarify the regulatory requirements that apply.

The HRA recently held a regenerative medicine event hosted by the Cell Therapy Catapult to look at changes and discuss issues with the sector, regulators and representative bodies. Additionally in 2012, the MHRA hosted an event on the regulation of regenerative medicine [external link].

As set out in the Government Response to the House of Lords Inquiry [external link] a Regenerative Medicine Expert Group (RMEG) is being established to develop an NHS regenerative medicine delivery readiness strategy and action plan. This group will build on existing initiatives so that the NHS is fully prepared to deliver these innovative treatments. The group will be supported by the Department of Health; members will be drawn from a number of groups and organisations, including the HRA. The remit of the Regenerative Medicine Expert Group will include a role to monitor the effect of regulation on the development of regenerative medicines in the UK.

More generally, the HRA is working in partnership with a range of organisations to improve the environment for research in the UK. Please refer to our projects and plans pages for more information.

During 2012-13, the House of Lords Science and Technology Committee held an inquiry into regenerative medicine in the UK. For more information about the inquiry, the resulting report and the HRAs responses please use the links below:

UK Stem Cell Toolkit [external link]This toolkit is intended to be a reference tool for those who wish to develop a programme of human stem cell research and manufacture, including clinical applications. It applies only to the regulation of human stem cells and their use in the laboratory and clinical settings. The toolkit provides regulatory routemaps that are specific to individual stem cell projects. It does this by using your responses to questions when you start using the toolkit.

Clinical Trials Toolkit [external link]This toolkit provides practical advice to researchers in designing and conducting publicly funded clinical trials in the UK. It provides information on best practice and outlines the current legal and practical requirements for conducting clinical trials. The toolkit is primarily focused on Clinical Trials of Investigational Medicinal Products (CTIMPs) and the regulatory environment and requirements associated with these. However researchers and R&D staff working on trials in other areas will also find useful information and guidance of relevance to the wider trials environment.

Cell Therapy Catapult [external link]The Cell Therapy Catapult was established in 2012 to grow the UK cell therapy industry. It was set up to help businesses take innovative ideas through to commercialisation. The website has specific regulatory resource pages, which include an overview of the relevant regulations for cell therapy.

MHRA Innovation Office [external link]The MHRA Innovation Office helps organisations that are developing innovative medicines, medical devices or using novel manufacturing processes to navigate the regulatory processes in order to be able to progress their products or technologies. Examples of innovative products include Advanced Therapy Medicinal Products (ATMPs), nanotechnology, stratified medicines, novel drug/device combinations, and advanced manufacturing.

UK Regenerative Medicine Platform (UKRMP) [external link]The Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Science Research Council (EPSRC) have established the UKRMP to address the challenges associated with translating scientific discoveries towards clinical impact.

UK Stem Cell Bank [external link]The UK Stem Cell Bank was established to provide a repository of human embryonic, foetal and adult stem cell lines as part of the UK governance for the use of human embryos for research. Its role is to provide quality controlled stocks of these cells that researchers worldwide can rely on to facilitate high quality and standardised research. It also prepares stocks of EUTCD-Grade cell lines for use as starting materials for the development of cellular therapies. The UK Stem Cell Bank is hosted by NIBSC [external link], which is part of the MHRA.

UK Trade & Investment (UKTI) Life Science Investment Organisation (LSIO) [external link]This dedicated unit within UKTI is intended to support overseas companies to invest and expand in the UK from the earliest research and development collaborations through to clinical trials, commercial operations and partnerships.

Knowledge Transfer Network (KTN) Regenerative Medicine Priority Area [external link]This is an official group within the Healthtechnologies and Medicine Knowledge Transfer Network (KTN). Knowledge Transfer Networks have been set up by the Technology Strategy Board (TSB) to facilitate collaboration and stimulate innovation by bringing together people from a range of organisations with a variety of expertise.

DEFRA Advisory Committee on Releases to the Environment (ACRE) [external link]

HSE Scientific Advisory Committee on Genetically Modified Organisms (Contained Use) (SACGM (CU) [external link].

MHRAs Clinical Trials, Biologicals and Vaccines Expert Advisory Group[external link]

Regenerative Medicine Expert Group [external link]

Visit link:
Regenerative Medicine - Health Research Authority

Dr. Angelo TellisCosmetic Surgeon and Regenerative Medicine Specialist

Aegean Medical offers all natural, high tech procedures with a European flair to meet your cosmetic and orthopedic needs! Aegean procedures are less invasive than traditional plastic or orthopedicsurgery with much less downtime and recovery.

Aegean Cosmeticspecializes in Liposuction, Lipotransfernatural breast and buttock augmentations, Scarless Breast Reductions, and powerful skin care treatments like PRP (platelet rich plasma) facials, Dermapen microneedling, and RF (radio frequency) skin tightening. Aegean Cosmetic can also perform PRP treatment to help promote hair restorationas well.

Aegean Orthopedic provides treatments using yourbodys own stem cells and PRP to repair damage and regrow cartilage for knees, shoulders, hips, and a variety of otherconditions where degeneration or tissue damage has occurred. Orthopedic treatments are normally completed in the office setting within 1-2 hours!

Advantages Tumescent liposuction and breast enhancement in one procedure. All natural- nothing artificial is used. Safe and gentle procedure. Enhancement looks and feels like natural breasts. Future breast feeding not affected. Rapid recovery. Permanent, selective treatment of problem areas with smooth, even results. Virtually no scarring at insertion sites. Significantly reduced risk of complications. Comfortable outpatient procedure. Less bleeding, bruising and swelling.

Fourlocations to serve you Aegean Medical is located in Morehead City, New Bern, Jacksonville, and CaryNC and operates under the Crystal Coast Pain Management and Azura Skin Caresystem and supporting providers .

Read the rest here:
Aegean Medical by Dr. Angelo Tellis

The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to this new report. Increased prevalence of neurodegenerative, orthopedic, and other aging-related disorders in geriatric population coupled with rising global geriatric population is anticipated to drive market growth.

Developments in biotechnology have enabled gaining in-depth knowledge pertaining to cell division and differentiation as well as the metabolism mechanism of various cells. This enriched knowledge, coupled with emergence of novel streams of biotechnology such as gene therapy and nanotechnology, further prospered use of cell-based technology in therapeutic treatment.

Identification of ability of stem cells to develop into various different cell lines further propelled the advancements in regenerative medicine. Frequent media exposure due to regulatory as well as ethical controversies around embryonic stem cells has increased awareness among the masses. This encouraged researchers to explore and develop other potential fields for similar applications, such as induced pluripotent stem cells (iPSC).

Furthermore, the emergence of gene therapy techniques with potential to rectify and restore effects of gene mutations in cells is under development. Conditions caused due to Single Nucleotide Polymorphism (SNP) as well as mutations that induce degenerative characteristics are primarily targeted.

Companies Mentioned

Key Topics Covered:

1 Research Methodology

2. Executive Summary

3. Regenerative Medicnie Market Variables, Trends & Scope

4. Regenerative Medicine Market: Product Type Estimates & Trend Analysis

5. Regenerative Medicine Market: Therapeutic Category Estimates & Trend Analysis

6. Regenerative Medicine Market: Regional Estimates & Trend Analysis, by Product And Therapeutic Category

7. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/948x9s/regenerative

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/regenerative-medicine-market-to-reach-55-billion-by-2025-increased-prevalence-of-neurodegenerative-orthopedic--other-aging-related-disorders-300506534.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Here is the original post:
Regenerative Medicine Market to Reach $5.5 Billion by 2025 ... - PR Newswire (press release)

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research, and the growing need for cost-effective drug discovery and development. On the other hand, the growth of this market is hindered to some extent due to the high cost of automation and issues related to biospecimen sample procurement.

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

"Automated storage is expected to register the highest CAGR during the forecast period" The biobanking market is classified by storage type into manual and automated storage. The automated storage type segment is expected to grow at a higher rate during the forecast period. This is attributed to launch of new and advanced automated storage equipment and increasing demand for the quality storage of samples.

"Regenerative medicine to dominate the market during the forecast period"The biobanking market is segmented based on applications regenerative medicine, life science research, and clinical research. In 2017, the regenerative medicine segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to other segments. This can be attributed to increasing research activities in the field of regenerative medicine and rising demand for well-annotated and quality biosamples for research.

"Asia-Pacific is estimated to grow at the highest CAGR during the forecast period" Geographically, the biobanking market is dominated by North America, followed by Europe. The Asia-Pacific region is estimated to grow at the fastest rate which can be attributed to the large population in China and India, increasing research in regenerative medicine, and improving life sciences research infrastructure in the region.

The primary interviews conducted for this report can be categorized as follows:

The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Study Coverage:The report analyses the biobanking market by product and service, sample type, storage type, application and regions. Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market.

Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the type, products, applications, end users, and regions.

Key benefits of buying the Report:This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: rel="nofollow">clare@reportlinker.comUS:(339) 368 6001 Intl:+1 339 368 6001

View original content:http://www.prnewswire.com/news-releases/biobanking-market-by-product-and-serviceequipment-consumables-services-software-sample-type-blood-products-human-tissues-cell-lines-nucleic-acids-application-regenerative-medicine-life-science-clinical-research---g-300505662.html

SOURCE Reportlinker

More here:
Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood ... - Markets Insider